bio med and cml treatment

Sobre esta actividad

Creada por

paankhuri bhatia

Reino Unido

Descarga la versión para jugar en papel

Top 10 resultados

Todavía no hay resultados para este juego. ¡Sé el primero en aparecer en el ranking! Inicia sesión para identificarte.

Crea tu propio juego gratis desde nuestro creador de juegos

Compite contra tus amigos para ver quien consigue la mejor puntuación en esta actividad

Crear reto

Uso de HA y A

Paula Bravo

España

(35)

Haz clic en A o HA que aparecen en la columna de la derecha, según corresponda en el texto.
Past Simple

Miguel Angel

Colombia

(53)

Completa las frases con la forma correcta del verbo que se encuentra entre paréntesis.
OPEN UP 4 - UNIT 3 GRAMMAR (Countable and uncountable nouns)

karen blixen

España

(22)

Repasamos la gramática de la unidad.
Escribe las letras que faltan

deborah olano

Uruguay

(25)

Se debera completar la palabra,colocando las letras que faltan.
Ajuste de reacciones quimicas

aurora martin

España

(27)

En esta actividad se deberan de ajustar las siguientes reacciones químicas


Completar Frases bio med and cml treatmentVersión en línea bio med and cml treatment por paankhuri bhatia 1 Chronic myeloid leukaemia ( CML ) is a myeloproliferative disorder caused by the , which results from formation of the - fusion gene . This gene encodes active , which causes uncontrolled proliferation of cells . The main treatment for CML is biological therapy in the form of ( TKIs ) . The first - line treatment is , a TKI that works by competitively inhibiting the - of the BCR - ABL tyrosine kinase , preventing of downstream signalling and abnormal cell growth . Imatinib is indicated as first - line therapy in , but it may be contraindicated or poorly tolerated in patients with significant , , or due to adverse effects such as or symptoms . In patients who develop or intolerance to Imatinib , second - generation TKIs such as Dasatinib and Nilotinib may be used . Dasatinib is a more TKI that inhibits BCR - ABL as well as SRC family kinases but it is contraindicated in patients at risk of or . Nilotinib is another second - generation TKI that selectively inhibits BCR - ABL tyrosine kinase and may be used as an alternative first - line agent or in Imatinib resistance , although it is contraindicated in patients with or significant disease . Bosutinib is an additional second - generation TKI used in later - line therapy for patients to multiple TKIs , and its use may be limited by and side effects . Ponatinib is a third - generation TKI specifically effective against the T315I mutation of BCR - ABL , which confers resistance to other TKIs , and is indicated in , but it is contraindicated in patients with high risk due to increased risk of . In situations where TKIs are unsuitable , such as , Interferon - ? may be used as a biological therapy , as it works by modulating the immune response and inhibiting myeloid proliferation , although it is less and associated with - like side effects and symptoms . 2 jehbfhksbfks aeifb aifb aibf bjasfkjsfbjksdbf sbfjlsbfls iosfbjslf isbfsbf . s f 3 ekjfbksd sdubfkjsbf ioshfjsbf soiufgsjbfsalfnalsf . . svfjdskbfljsf oiashbfoisbfas oisfboaisfb asjlfaef .

Completar Frases

bio med and cml treatmentVersión en línea

bio med and cml treatment

Chronic myeloid leukaemia ( CML ) is a myeloproliferative disorder caused by the , which results from formation of the - fusion gene . This gene encodes active , which causes uncontrolled proliferation of cells . The main treatment for CML is biological therapy in the form of ( TKIs ) . The first - line treatment is , a TKI that works by competitively inhibiting the - of the BCR - ABL tyrosine kinase , preventing of downstream signalling and abnormal cell growth . Imatinib is indicated as first - line therapy in , but it may be contraindicated or poorly tolerated in patients with significant , , or due to adverse effects such as or symptoms . In patients who develop or intolerance to Imatinib , second - generation TKIs such as Dasatinib and Nilotinib may be used . Dasatinib is a more TKI that inhibits BCR - ABL as well as SRC family kinases but it is contraindicated in patients at risk of or . Nilotinib is another second - generation TKI that selectively inhibits BCR - ABL tyrosine kinase and may be used as an alternative first - line agent or in Imatinib resistance , although it is contraindicated in patients with or significant disease . Bosutinib is an additional second - generation TKI used in later - line therapy for patients to multiple TKIs , and its use may be limited by and side effects . Ponatinib is a third - generation TKI specifically effective against the T315I mutation of BCR - ABL , which confers resistance to other TKIs , and is indicated in , but it is contraindicated in patients with high risk due to increased risk of . In situations where TKIs are unsuitable , such as , Interferon - ? may be used as a biological therapy , as it works by modulating the immune response and inhibiting myeloid proliferation , although it is less and associated with - like side effects and symptoms .

jehbfhksbfks aeifb aifb aibf bjasfkjsfbjksdbf sbfjlsbfls iosfbjslf isbfsbf . s f

ekjfbksd sdubfkjsbf ioshfjsbf soiufgsjbfsalfnalsf . . svfjdskbfljsf oiashbfoisbfas oisfboaisfb asjlfaef .

Puedes integrar el juego en un LMS compatible con LTI 1.1 o LTI 1.3 como Canvas, Moodle, o Blackboard. De esta manera podrás guardar las puntuaciones automáticamente en el libro de calificaciones de esa plataforma.

bio med and cml treatment

Completar Frases

Sobre esta actividad

Creada por

Descarga la versión para jugar en papel

Top juegos

Completar Frases

Uso de HA y A

Completar Frases

Past Simple

Completar Frases

OPEN UP 4 - UNIT 3 GRAMMAR (Countable and uncountable nouns)

Completar Frases

Escribe las letras que faltan

Completar Frases

Ajuste de reacciones quimicas

Completar Frases

bio med and cml treatmentVersión en línea

por paankhuri bhatia

		%
	Anónimo	%
		%
		%